Mao W, Chen J, Zheng M, Wu B, Zhu Y
Lung Transplant Group, Wuxi People's Hospital, Nanjing Medical University, Management of Registered Lung Transplant Unit, Wuxi, China.
Transplant Proc. 2013 Jan-Feb;45(1):349-55. doi: 10.1016/j.transproceed.2012.02.045.
Lung transplantation (LT) remains the only available option for patients with end-stage lung disease. Until recently, 244 lung transplantations have been performed at approximate 20 institutes in China. The aim of this article was to present the initial experience of LT at a single center in China.
We performed a retrospective review of the database from The Chinese Organ Transplantation Network between January 1978 and December 2010 with detailed records available at our center.
We performed 100 of 244 lung transplantions at the Wuxi Center, The remaining procedures were performed at other institutes. The overall survival rates for these patients at 1, 2, 3, and 5 years were 73.3%, 61.6%, 53.5%, and 40.7%, respectively. The indications for lung transplantation included idiopathic pulmonary fibrosis (n = 47), chronic obstructive pulmonary disease (n = 33), silicosis (n = 5), bronchiectasis (n = 5), and Eisenmenger's syndrome (n = 4). The procedure types consisted of single-lung transplantations (s; n = 72), and bilateral lung transplantations (s; n = 28). Cardiopulmonary bypass was required in 5 patients, whereas 56 required arteriovenous extracorporeal membrane oxygenation, including extended use in 3 before and 10 after LT. The main morbidities and complications after LT were sepsis (n = 11), primary graft dysfunction (PGD, n = 10), anastomotic stenosis (n = 10), acute rejection episodes (n = 25), and bronchiolitis obliterans syndrome (n = 15). In-hospital mortality was 18%, including sepsis (n = 10), PGD (n = 6), acute rejection episode (n = 1) and pulmonary infarction (n = 1). The mean survival time was 3.4 years.
In China, lung transplantation may offer a viable therapy for patients with various end-stage pulmonary conditions. The initiation of LT should focus on improving the survival rate by increased clinical practice.
肺移植(LT)仍是终末期肺病患者唯一可行的治疗选择。直到最近,中国约20家机构已开展了244例肺移植手术。本文旨在介绍中国某单一中心肺移植的初步经验。
我们对中国器官移植网络1978年1月至2010年12月的数据库进行了回顾性分析,我们中心有详细记录。
在无锡中心进行了244例肺移植中的100例,其余手术在其他机构进行。这些患者1年、2年、3年和5年的总生存率分别为73.3%、61.6%、53.5%和40.7%。肺移植的适应证包括特发性肺纤维化(n = 47)、慢性阻塞性肺疾病(n = 33)、矽肺(n = 5)、支气管扩张症(n = 5)和艾森曼格综合征(n = 4)。手术类型包括单肺移植(n = 72)和双肺移植(n = 28)。5例患者需要体外循环,而56例需要动静脉体外膜肺氧合,包括3例在肺移植前和10例在肺移植后延长使用。肺移植后的主要发病率和并发症为败血症(n = 11)、原发性移植物功能障碍(PGD,n = 10)、吻合口狭窄(n = 10)、急性排斥反应(n = 25)和闭塞性细支气管炎综合征(n = 15)。住院死亡率为18%,包括败血症(n = 10)、PGD(n = 6)、急性排斥反应(n = 1)和肺梗死(n = 1)。平均生存时间为3.4年。
在中国,肺移植可能为各种终末期肺部疾病患者提供一种可行的治疗方法。肺移植的开展应注重通过增加临床实践提高生存率。